Compare Evergy Inc. Common Stock (EVRG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Evergy Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Evergy Inc. Common Stock trades at $82.56 (market cap $18.94B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Evergy Inc. Common Stock is far larger — about 3.9× Travere Therapeutics Inc. Common Stock's market cap, and Evergy Inc. Common Stock pays a 3.38% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Evergy Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EVRG | TVTX | |
|---|---|---|
Market Cap | $18.94B | $4.88B |
Volume | 1,640,293 | 1,668,577 |
Sector | Utilities | Health |
52-Week High | $88.13 | $67.52 |
52-Week Low | $72.31 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $35.41B | $5.01B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Evergy (EVRG) trades at $82.13, up 0.77% today, with a bullish technical signal and strong support near $80. The stock shows solid fundamentals with a P/E of 20.9 and net income margin of 15.19%, supported by recent earnings beats in Q1 and Q2 2026. Positive sentiment is driven by data center demand growth and a $21.6 billion investment plan, as highlighted in recent news.
The outlook for EVRG is positive, with analyst consensus pointing to a $89.83 price target and 38.89% buy ratings. Key opportunities include load growth from data center contracts and projected 6-8% EPS growth through 2030. Risks involve regulatory challenges, high capital expenditures, and potential volatility from interest rate sensitivity.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Evergy Inc. Common Stock
Evergy is a regulated electric utility serving customers in Kansas and Missouri. Its operations include electricity generation, transmission, and distribution through its integrated utility subsidiaries.
Read more on EVRG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
